{"id":"W2382331405","doi":"10.1200/jco.2015.33.7_suppl.139","title":"Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Docetaxel; Internal medicine; Hazard ratio; Cabazitaxel; Enzalutamide; Urology; Prednisone; Oncology; Cancer; Gastroenterology; Randomized controlled trial; Androgen deprivation therapy; Confidence interval; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00693765,0.001507991,0.004794335,0.0005707048,0.0003956265,0.001413669,0.001080038,0.001608746,0.006628498],"category_scores_gemma":[0.006442648,0.0006341243,0.007682004,0.0004820599,0.0007776038,0.0009314203,0.0005965127,0.002461262,0.0008161553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001362588,"about_ca_system_score_gemma":0.001251786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007623299,"about_ca_topic_score_gemma":0.001921525,"domain_scores_codex":[0.9972456,0.001749812,0.0001805597,0.0003315815,0.0002477602,0.0002447156],"domain_scores_gemma":[0.9953865,0.002082084,0.0008462753,0.0003913549,0.0003621185,0.0009316453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9823734,0.001318705,0.001436057,0.0004091981,0.003141809,0.0000406123,0.00003577105,0.0006400959,0.001698176,0.00006589896,0.0005379515,0.008302378],"study_design_scores_gemma":[0.6799814,0.2834292,0.0180684,0.00008679095,0.009818919,0.0001486742,0.00005561894,0.003076216,0.002747002,0.0003630031,0.002181393,0.00004338048],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813912,0.005496475,0.001428682,0.000934489,0.0004394711,0.003645832,0.003879083,0.0002067179,0.002578148],"genre_scores_gemma":[0.9898816,0.0009910224,0.001632004,0.0005824034,0.0002335091,0.001748681,0.00286812,0.00003827752,0.002024352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00693765,"threshold_uncertainty_score":0.03669024,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2350423210612337,"score_gpt":0.484388637088961,"score_spread":0.2493463160277273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}